[1]
|
Tome AM,Filipe A. Quinolones:review of psychiatric and neurological adverse reactions[J]. Drug Saf,2011,34(6):465-484. |
[2]
|
张霞光,李天云. 喹诺酮类抗菌药在临床使用中的不良反应[J].国外医药(抗生素分册),2003,24:30-33. |
[3]
|
Kim J,Ohtani H,Tsujimoto M. Quantitative comparison of the convulsive activity of ombinations of twelve fluoroquinolones with five nonsteroidal antiinflammatory agents[J].Drug Metab Pharmacok,2009,24(2):167-174. |
[4]
|
陈翠环,潘宁开. 喹诺酮类药物诱发精神症状的回顾性分析[J].实用医技杂志,2008,15(10):1278-1279. |
[5]
|
操银针. 喹诺酮类药物引起神经系统不良反应358例分析[J].医药导报,2007,26(10):1246-1247. |
[6]
|
Ray WA,Murray KT,Hall,et al. Azithromycin and the risk of cardiovascular death[J].N Engl J Med,2012,366:1881-1890. |
[7]
|
Lapi F,Wilchesky M, Kezouh A,et al. Fluoroquinolones and the risk of serious arrhythmia: a population-based study[J].Clin Infect Dis,2012,55:1457-65. |
[8]
|
Adefurin A,Sammons H,Jacqz-Aigrain E,et al. Ciprofloxacin safety in paediatrics: a systematic review[J].Arch Dis Child,2011,96:874-80. |
[9]
|
Schaad UB. Will fluoroquinolones ever be recommended for common infections in children?[J].Pediatr Infect Dis J,2007,26:865-867. |
[10]
|
Pichichero ME,Arguedas A, Dagan R,et al. Safety and efficacy of gatifloxacin therapy for children with recurrent acute otitis media (AOM) and/or AOM treatment failure[J].Clin Infect Dis, 2005,41:470-478. |
[11]
|
Seeger JD,West WA,Fife D,et al. Achilles tendon rupture and its association with fluoroquinolone antibiotics and other potential risk factors in amanaged care population[J]. Pharmacoepidemiol Drug Safe,2006,15:784-792. |
[12]
|
Wise BL,Peloquin C,Choi H,et al. Impact of age,obesity,and steroiduse on quinolone-associated tendon disorders[J].Am J Med,2012,125:23-28. |
[13]
|
Mandell LA,Ball P,Tillotson G. Antimicrobial safety and toler ability:differences and dilemmas[J].Clin Infect Dis,2001,32(Suppl):72-79. |
[14]
|
Paterson JM,Mamdani MM, Manno M,et al. Fluoroquinolone therapy and idiosyncratic acute liver injury: a population-based study[J].CMAJ,2012,184:1565-1570. |
[15]
|
Etminan M, Forooghian F,Brophy JM,et al. Oral fluoroquinolones and the risk of retinal detachment[J].JAMA, 201,307:1414-1419. |
[16]
|
Albini TA,Karakousis PC,Abbey AM,et al. Association between oral fluoroquinolones and retinal detachment[J].Am J Ophthalmol, 2012,154:919-921. |
[17]
|
Christ W, Lehnert T,Ulbrich B. Specific toxicologic aspects of the quinolones[J].Rev Infect Dis,1988,10:141-146. |
[18]
|
Kato M,Onodera T. Morphological investigation of cavity formation in articular cartilage induced by ofloxacin in rats[J].Fundam Appl Toxicol,1988,11 (1):110-119. |
[19]
|
Grady R. Safety profile of quinolone antibiotics in the pediatric population[J].Pediatr Infect Dis,2003,22 (12):1128-1132. |
[20]
|
van der Linden PD, Sturkenboom MC, Herings RM,et al. Fluoroquinolones and risk of achilles tendon disorders:case-control study[J].BMJ,2002, 324(7349):1306-1307. |
[21]
|
Shaughnessy MK,Amundson WH, Kuskowski MA,et al. Unnecessary antimicrobial use in patients with current or recent Clostridium difficile infection[J].Infect Control Hosp Epidemiol,2013,34:109-116. |